OBI Pharma To Forge Ahead With Cancer Vaccine In Face Of Study Failure
This article was originally published in Scrip
Taiwanese biotech OBI Pharma plans to plough on with a Phase III study of its investigational cancer vaccine OBI-822/821, despite it failing to meet the primary endpoint in a Phase II/III study. The firm's share price fell by from TWD681 to close at TWD613 on Feb. 22 and slipped a further 9.95% to close at TWD522 on Feb. 23 on Taiwan's GreTai Securities Market following the news.
You may also be interested in...
With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.